Debevoise Advises Blackstone in Its Investment in Medable, Valuing Medable at $2.1 Billion

26 October 2021

Debevoise & Plimpton LLP is advising Blackstone Growth in connection with a $304 million Series D investment, along with other investors, in Medable Inc., the leading cloud platform for patient-centered clinical research, valuing Medable at $2.1 billion. The funding is intended to accelerate the global adoption of digital and decentralized clinical trials, enabling ubiquitous access to the latest treatments for every body and every biology. For more information, please see the company’s press release.

Medable’s mission is to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies.

The Debevoise team is led by M&A partners Spencer Gilbert and Kevin Rinker and counsel David Iozzi and includes counsel Kim Le and associates Aleena Aspervil, Hannah Levine, James Malmo and Sergio Torres, intellectual property partner Henry Lebowitz, counsel Judith Church and associate Paisley Piasecki, benefits partner Meir Katz and associate Matthew Trudeau, tax partner Peter Furci, FDA regulatory partner Paul Rubin and associate Melissa Runsten, data strategy and security international counsel Christopher Garrett and counsel Johanna Skrzypczyk and litigation associate David Wang.